You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. BM: Biomedical Technologies (BM)

    Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023

    The Biomedical Technologies topic aims to support the early-stage development of novel products, processes, or services that will enable the delivery of high-quality, economically-efficient healthcare. Subtopics are not aimed at supporting or conducting clinical trials, clinical efficacy or safety studies, the development pre-clinical or clinical-stage drug candidates or medical devices, or work p ...

    SBIR/STTRPhase INational Science Foundation
  2. CBD233-001: Blister Chemical Warfare Agent Disclosure Spray System

    Release Date: 08-23-2023Open Date: 09-20-2023Due Date: 10-18-2023Close Date: 10-18-2023

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Biotechnology OBJECTIVE: Develop a chemical warfare agent (CWA) disclosure spray system with the capability to visually disclose the location of blister CWA contamination on surfaces. DESCRIPTION: Warfighters need to remove blister CWA contamination as quickly as possible and to reduce the logistical burden to warfighters for decontamination processes, per ...

    SBIRPhase I/Phase IIDepartment of DefenseOffice for Chemical and Biological Defense
  3. DL2: Blockchain, DAGs, and Next-Gen Protocols

    Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023

    NA

    SBIR/STTRPhase INational Science Foundation
  4. PAR-21-282: Blueprint Medtech: Small Business Translator (U44- Clinical Trial Optional)

    Release Date: 08-20-2021Open Date: 09-20-2021 Due Dates: Multiple Close Date: 06-21-2024

    Blueprint MedTech The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). Innovators developing groundbreaking medical ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-21-233: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 04-23-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-21-162: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 03-29-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. CBD233-004: Breathable, Non-Fluorinated Chemical Barrier Materials

    Release Date: 08-23-2023Open Date: 09-20-2023Due Date: 10-18-2023Close Date: 10-18-2023

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Biotechnology OBJECTIVE: Develop a non-fluorinated chemical protective material that meets the Class 3 requirements set forth in National Fire Protection Association (NFPA) 1994 standard. DESCRIPTION: The Government requires ensembles that will meet the requirements for Class 3 protection as defined in NFPA 1994, Standard for Protective Ensembles for Hazar ...

    SBIRPhase I/Phase IIDepartment of DefenseOffice for Chemical and Biological Defense
  8. HR0011SB20234XL-03 : Bright ELectron and Light Sources (BELLS)- SBIR XL

    Release Date: 11-15-2022Open Date: 11-15-2022Due Date: 12-31-2023Close Date: 12-31-2023

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Biomedical OBJECTIVE: The goal of BELLS is to demonstrate and commercialize practical sources of intense, tunable electrons and monochromatic hard x-rays. These sources would support transformative capabilities for applications such as non-destructive inspection, medical diagnostics, and treatments. DESCRIPTION: BELLS will develop compact sources of monoen ...

    SBIRPhase I/Phase IIDepartment of DefenseDefense Advanced Research Projects Agency
  9. NIH/NCI 465: Cancer Prevention and Treatment Clinical Trials Tools for Recruitment and Retention of Diverse Populations

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will be accepted. Number of anticipated awards: 3-5 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary Slow and incomplete accrual of diverse participants to cancer pre ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. A234-009: Casualty Care Training- Mixed Reality Manikin Solution for Female Soldier Survivability

    Release Date: 11-15-2022Open Date: 11-15-2022Due Date: 12-31-2023Close Date: 12-31-2023

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Combat Casualty Care; Human-Machine Interfaces OBJECTIVE: Develop, demonstrate, and deliver solutions for enhanced female combat trauma mixed reality (MR) training manikin that incorporates open architecture utilizing high fidelity simulations for combat-trauma-related scenarios. DESCRIPTION: A study of the Army’s medical training literature found signif ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
US Flag An Official Website of the United States Government